Patents by Inventor Ningxin Yan

Ningxin Yan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20250017875
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: September 30, 2024
    Publication date: January 16, 2025
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • Liquid naloxone spray
    Patent number: 11975096
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: May 7, 2024
    Assignee: Hikma Pharmaceuticals USA Inc.
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
  • Stable cannabinoid formulations
    Patent number: 11911361
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: February 27, 2024
    Assignee: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • EPINEPHRINE SPRAY FORMULATIONS
    Publication number: 20230390218
    Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.
    Type: Application
    Filed: August 22, 2023
    Publication date: December 7, 2023
    Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
  • Epinephrine spray formulations
    Patent number: 11771663
    Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: October 3, 2023
    Assignee: Hikma Pharmaceuticals USA Inc.
    Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
  • LIQUID NALOXONE SPRAY
    Publication number: 20230181457
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Application
    Filed: February 14, 2023
    Publication date: June 15, 2023
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
  • Liquid naloxone spray
    Patent number: 11628139
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: April 18, 2023
    Assignee: Hikma Pharmaceuticals USA Inc.
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
  • Liquid naloxone spray
    Patent number: 11617713
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: April 4, 2023
    Assignee: Hikma Pharmaceuticals USA Inc.
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
  • Epinephrine spray formulations
    Patent number: 11571384
    Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 7, 2023
    Assignee: Hikma Pharmaceuticals USA Inc.
    Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
  • LIQUID NALOXONE SPRAY
    Publication number: 20230008410
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Application
    Filed: August 25, 2021
    Publication date: January 12, 2023
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
  • Epinephrine spray formulations
    Patent number: 11517525
    Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: December 6, 2022
    Assignee: Hikma Pharmaceuticals USA Inc.
    Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20220280446
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: February 18, 2022
    Publication date: September 8, 2022
    Applicant: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20220184215
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 16, 2022
    Applicant: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar VANGARA, Huaguang LI, Ningxin YAN, Hung Q. Nguyen, Venkat R. GOSKONDA
  • Stable cannabinoid formulations
    Patent number: 11331279
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: May 17, 2022
    Assignee: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20220125932
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: November 5, 2021
    Publication date: April 28, 2022
    Applicant: RADIUS PHARMACEUTICALS INC.
    Inventors: Kiran Kumar VANGARA, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20220054450
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: November 5, 2021
    Publication date: February 24, 2022
    Applicant: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • Stable cannabinoid formulations
    Patent number: 11224660
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: January 18, 2022
    Assignee: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • LIQUID NALOXONE SPRAY
    Publication number: 20210353533
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Application
    Filed: March 11, 2021
    Publication date: November 18, 2021
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
  • STABLE CANNABINOID FORMULATIONS
    Publication number: 20210330797
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Application
    Filed: July 6, 2021
    Publication date: October 28, 2021
    Applicant: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • Liquid naloxone spray
    Patent number: 11135155
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: October 5, 2021
    Assignee: Hikma Pharmaceuticals USA Inc.
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda